Exploring how complement proteins affect kidney disease in diabetes
Official title: Understanding the role of the Complement Proteome in progressive Diabetic Kidney Disease
Funded at Joslin Diabetes Center · NIH-10809603 · Data updated 2026-11-12
This study is looking at how certain proteins in your urine might help us understand and track kidney problems in people with diabetes, with the hope of finding new ways to protect your kidneys from damage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Joslin Diabetes Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 30, 2020 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $351,902 |
| NIH project number | 5R01DK123459-05 |
| Project ID | NIH-10809603 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with diabetes who are experiencing or at risk of developing diabetic kidney disease.
✕Less likely to help
Patients without diabetes or those who do not have any signs of kidney disease may not benefit from this research.
What this research studies
This research investigates the role of complement proteins in the progression of diabetic kidney disease (DKD). By analyzing urine samples from patients with diabetes, the study aims to identify specific inflammatory markers that could indicate the risk of developing end-stage renal disease (ESRD). The researchers will use advanced proteomic technology to evaluate the urinary complement proteome over a long-term follow-up period. This approach may help uncover new targets for interventions to slow or prevent kidney damage in diabetic patients.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or slow the progression of kidney disease in patients with diabetes.
How similar studies have gone: Previous studies have shown promise in identifying inflammatory markers related to diabetic kidney disease, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Joslin Diabetes Center
Boston, United States Active
Researchers
- Principal investigator: Niewczas, Monika Anna — Joslin Diabetes Center
- Study coordinator: Niewczas, Monika Anna
Related research
Other NIH-funded projects on the same topics.
-
siRNA nanoparticle treatment to stop diabetic kidney damage
A new nanoparticle-delivered gene-silencing treatment aims to lower kidney inflammation in people with diabetes to help protect their kidneys.
-
LRG1’s role in diabetic kidney disease and kidney fibrosis
A study examines how a specific protein, LRG1, influences kidney disease related to diabetes and its scarring, with the aim of finding targeted ways to slow or prevent damage.
-
Genetic discovery for diabetic kidney disease in adults
A scientist team is studying the genes that influence diabetic kidney disease in adults to better understand why some people develop it.
-
Non-canonical NF-kB and inflammation in diabetic kidney disease
A study to understand how a specific inflammatory pathway worsens kidney disease in adults with type 2 diabetes and how it might be treated.
-
Epidermal microfluidic screen to detect diabetic kidney disease
A new skin-based microfluidic test platform may help identify kidney complications in people with diabetes using real-time biomarkers from sweat and glucose data.
-
PFAS exposure and kidney disease risk in teens with type 2 diabetes
Aging and kidney health study in youths with type 2 diabetes to see how a common chemical (PFAS) affects kidney risk and how to prevent or treat it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.